The story presents a conundrum. Plaintiffs file a class action, which the defendant initially resists. Plaintiffs counsel spends hundreds of thousands of dollars (or more) in lodestar and costs ...
On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA). This Agreement resolves the patent litigation ...
Teva cannot market its generic version of Firdapse in the U.S. before February 25, 2035, unless specific conditions arise. Ongoing Firdapse patent litigation continues against Hetero and Lupin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback